Loading stock data…
Aclaris Therapeutics, Inc. (ACRS)
$5.04+0.05 (+0.90%)
Market OpenUpdated 2:07 PM EDT
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aclaris Therapeutics, Inc. in the Healthcare sector is trading at $5.04 with a market capitalization of $617M. Wall Street consensus targets $10.00 (10 analysts), implying a +98.2% move over the next 12 months. The stock is currently near its 52-week high of $5.15, remaining 51.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +98.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.00M↑ | $1.29M↓ | $3.30M↑ | $1.78M↑ | $1.46M |
| Gross Profit | $208,000↑ | -$174,000↓ | $850,000↑ | -$73,000↓ | -$61,000 |
| Operating Income | -$22.19M↑ | -$22.33M↓ | -$17.05M↓ | -$16.91M↑ | -$17.78M |
| Net Income | -$19.82M↓ | -$19.80M↓ | -$14.61M↑ | -$15.43M↓ | -$15.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$617.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.49%
Volume
Today's trading volume
674,958
Recent News
3 Penny Stocks Under $5 Backed by Real Revenue Growth
These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the top penny stocks to buy in investors’ stock portfolio. On May 8, Stifel reiterated a Hold rating on Aclaris Therapeutics Inc. (NASDAQ:ACRS) and increased the price target to $4 from $3. The price target hike underscores the research firm’s optimism about the company’s multi-targeting approaches and its […]
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?